117 related articles for article (PubMed ID: 15491285)
1. Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia.
Zwaan CM; Kaspers GJ
Br J Haematol; 2004 Nov; 127(3):264-79. PubMed ID: 15491285
[TBL] [Abstract][Full Text] [Related]
2. Treatment of childhood acute myeloid leukemia.
ter Bals E; Kaspers GJ
Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
[TBL] [Abstract][Full Text] [Related]
3. Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
Kaspers GJ; Zwaan CM
Haematologica; 2007 Nov; 92(11):1519-32. PubMed ID: 18024401
[TBL] [Abstract][Full Text] [Related]
4. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
5. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
8. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
[TBL] [Abstract][Full Text] [Related]
9. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
10. Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study.
Kaspers GJ; Zwaan CM; Veerman AJ; Rots MG; Pieters R; Bucsky P; Domula M; Göbel U; Graf N; Havers W; Jorch N; Kabisch K; Spaar HJ; Ritter J; Creutzig U
Klin Padiatr; 1999; 211(4):239-44. PubMed ID: 10472557
[TBL] [Abstract][Full Text] [Related]
11. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
12. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep.
Woods WG
Pediatr Blood Cancer; 2006 May; 46(5):565-9. PubMed ID: 16261562
[TBL] [Abstract][Full Text] [Related]
13. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel.
Stark B; Jeison M; Gabay LG; Mardoukh J; Luria D; Bar-Am I; Avrahami G; Kapeliushnik Y; Sthoeger D; Herzel G; Steinberg DM; Cohen IJ; Goshen Y; Stein J; Zaizov R; Yaniv I
Br J Haematol; 2004 Aug; 126(3):320-37. PubMed ID: 15257704
[TBL] [Abstract][Full Text] [Related]
14. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Larson RA
Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
[TBL] [Abstract][Full Text] [Related]
15. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia.
Marzac C; Teyssandier I; Calendini O; Perrot JY; Faussat AM; Tang R; Casadevall N; Marie JP; Legrand O
Clin Cancer Res; 2006 Dec; 12(23):7018-24. PubMed ID: 17145823
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute myeloid leukemia in older patients.
Roboz GJ
Expert Rev Anticancer Ther; 2007 Mar; 7(3):285-95. PubMed ID: 17338649
[TBL] [Abstract][Full Text] [Related]
17. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
Palmieri S; Ferrara F; Leoni F; Ciolli S; Pollio F; D'Amico MR; Celentano M; Viola A; Vicari L; Izzo B; Pane F
Hematol Oncol; 2007 Mar; 25(1):1-5. PubMed ID: 17036374
[TBL] [Abstract][Full Text] [Related]
18. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
19. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
[TBL] [Abstract][Full Text] [Related]
20. Acute leukaemia in children with Down syndrome: a population-based Nordic study.
Zeller B; Gustafsson G; Forestier E; Abrahamsson J; Clausen N; Heldrup J; Hovi L; Jonmundsson G; Lie SO; Glomstein A; Hasle H;
Br J Haematol; 2005 Mar; 128(6):797-804. PubMed ID: 15755283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
